aldh1a3

ALDH1A3-IN-2 is a potent ALDH1A3 inhibitor with an IC50 of 0.30 μM.ALDH1A3-IN-2 has potential for cancer disease research.

4-Isopropoxybenzaldehyde (compound 16), a powerful ALDH1A3 inhibitor with an IC50 of 0.26 μM (cell free assay), serves as an effective ALDH3A1 substrate. But shows weak antiproliferative effect against PC3, LNCaP, and DU145 PCa cell lines with IC50>200 μM[1].

NR6 is an innovative and potent ALDH1A3 inhibitor with high selectivity. It effectively suppresses the growth of mesothelioma multicellular spheroids and the recruitment of neutrophils.

ALDH1A3-IN-1 (Compound 14) is a potent inhibitor of ALDH1A3, with IC50 = 0.63 μM and Ki = 0.46 μM, and is utilized in prostate cancer research [1].

NCT-505 is a potent and selective inhibitor of aldehyde dehydrogenase (ALDH1A1, IC50 = 7 nM) and a weak inhibitor of hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 with IC50 values of >57 μM, 22.8 μM, 20.1 μM, and >57 μM, respectively.

D34-919 is a potent inhibitor of the ALDH1A3-PKM2 interaction, effectively inhibiting the ALDH1A3-mediated tetramerization enhancement of PKM2. Treatment mediated by D34-919 both in vitro and in vivo enhances and restores apoptosis and sensitivity in glioblastoma (GBM) cells induced by radiochemotherapy.

KOTX1 is an orally active and selective inhibitor of ALDH1A3. In a diabetic mouse model, KOTX1 improves glucose tolerance, insulin secretion, and blood glucose levels.

MCI-INI-3 is a selective competitive inhibitor of human ALDH1A3, with a Ki value of 0.55 μM for ALDH1A3 and 78.2 μM for ALDH1A1. It inhibits retinoic acid biosynthesis and can reduce the viability of glioblastoma cells GSC-83 and GSC-326.

CM10 is an aldehyde dehydrogenase 1A family(ALDH1A) inhibitor.